










































Fingolimod (FTY720) Enhances Remyelination Following
Demyelination of Organotypic Cerebellar Slices
Citation for published version:
Miron, VE, Ludwin, SK, Darlington, PJ, Jarjour, AA, Soliven, B, Kennedy, TE & Antel, JP 2010, 'Fingolimod
(FTY720) Enhances Remyelination Following Demyelination of Organotypic Cerebellar Slices' American
Journal Of Pathology, vol. 176, no. 6, pp. 2682-2694. DOI: 10.2353/ajpath.2010.091234
Digital Object Identifier (DOI):
10.2353/ajpath.2010.091234
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
American Journal Of Pathology
Publisher Rights Statement:
© 2010 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Cell Injury, Repair, Aging and Apoptosis
Fingolimod (FTY720) Enhances Remyelination
Following Demyelination of Organotypic Cerebellar
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Remyelination, which occurs subsequent to demyeli-
nation, contributes to functional recovery and is me-
diated by oligodendrocyte progenitor cells (OPCs)
that have differentiated into myelinating cells. Ther-
apeutics that impact remyelination in the CNS could
be critical determinants of long-term functional out-
come in multiple sclerosis (MS). Fingolimod is a S1P
receptor modulator in MS clinical trials due to sys-
temic anti-inflammatory properties, yet may impact
cells within the CNS by crossing the blood-brain bar-
rier. Previous studies using isolated dissociated cul-
tures indicate that neural cells express S1P receptors
and respond to receptor engagement. Our objective
was to assess the effects of fingolimod on myelin-
related processes within a multicellular environment
that maintains physiological cell-cell interactions, us-
ing organotypic cerebellar slice cultures. Fingolimod
treatment had no impact on myelin under basal con-
ditions. Fingolimod treatment subsequent to lysolec-
ithin-induced demyelination enhanced remyelination
and process extension by OPCs and mature oligoden-
drocytes, while increasing microglia numbers and
immunoreactivity for the astrocytic marker glial fibril-
lary acidic protein. The number of phagocytosing mi-
croglia was not increased by fingolimod. Using S1P re-
ceptor specific agonists and antagonists, we determined
that fingolimod-induced effects on remyelination and
astrogliosis were mediated primarily through S1P3 and
S1P5, whereas enhanced microgliosis was mediated
through S1P1 and S1P5. Taken together, these data dem-
onstrate that fingolimod modulates multiple neuroglial
cell responses, resulting in enhanced remyelination in
organotypic slice cultures that maintain the complex
cellular interactions of the mammalian brain. (Am J
Pathol 2010, 176:2682–2694; DOI: 10.2353/ajpath.2010.091234)
In the CNS, oligodendrocytes produce the myelin sheath,
which forms an insulating layer around axons to enhance
conduction velocity of electrical impulses.1–3 The mainte-
nance of myelin requires continuous turnover of its compo-
nents throughout life.4–5 Demyelinating insults contribute
to axonal degeneration, functional impairments, and clin-
ical disability in the autoimmune disease multiple sclero-
sis (MS).6–7 Neuropathological and magnetic resonance-
based observations indicate that re-ensheathment of
demyelinated axons, termed remyelination, occurs in de-
myelinated lesions in MS and may contribute to clinical
remittance.8–9 Remyelination is critical to restore electri-
cal impulse conduction and protect axons from degen-
eration or further injury.10–14 Experimental animal models
of CNS demyelination indicate that remyelination is me-
diated by oligodendrocytes generated from oligodendro-
cyte progenitor cells (OPCs).15 Demyelinating models
show that both astrocytes and microglia are critical for
remyelination, with microglia contributing to clearance of
debris and both cell types participating in creating an
environment permissive for remyelination.16–19
Supported by Novartis Pharma (Basel, Switzlerland), the Multiple Sclerosis
Society of Canada (J.P.A., T.E.K.), National Multiple Sclerosis Society
(J.P.A.), and Canadian Institutes of Health Research (studentship to V.E.M.).
Accepted for publication February 16, 2010.
This research was presented at the 2009 American Academy of Neu-
rology Annual Meeting with support from Novartis Pharma.
Supplemental material for this article can be found on http://ajp.
amjpathol.org.
Address reprint requests to Dr. Jack P. Antel, Room 111, Neuroimmu-
nology Unit, Montreal Neurological Institute, 3801 University St., Montreal,
QC, Canada, H3A 2B4, E-mail: jack.antel@mcgill.ca.
See related Commentary on page 2599 The American Journal of Pathology, Vol. 176, No. 6, June 2010Copyright © American Society for Investigative Pathology
DOI: 10.2353/ajpath.2010.091234
2682
The eventual failure of remyelination that occurs as MS
progresses may result from the generation of a nonper-
missive environment or intrinsic deficits in the remyelinat-
ing cells. Therapeutic agents that impact on myelin main-
tenance and remyelination are predicted to be important
determinants of long-term functional outcome in MS. Fin-
golimod (FTY720) is currently in clinical trials due to its
anti-inflammatory properties,20 yet readily crosses the
blood brain barrier.21 Analysis of the distribution of
fingolimod orally administered to mice for 1 week indi-
cated that the drug is sequestered in the brain paren-
chyma relative to the blood.22 Once fingolimod has
entered the brain, it is phosphorylated to its biologi-
cally active form which then binds sphingosine-1-phos-
phate (S1P) receptors.23–24
Previous experiments have demonstrated that isolated
neuroglial cell types in dissociated cultures can respond
to S1P receptor engagement. Both human and rodent
cells of the oligodendroglial lineage are able to respond
to fingolimod due to the expression of S1P receptor iso-
forms 1, 3, and 5.25–28 S1P or fingolimod treatment of
rodent pre-OLGs (O4/Galactocerebroside) or human
fetal OPCs (A2B5), respectively, leads to transient re-
traction of processes via S1P5.27,29 High doses of fingoli-
mod synergistically enhance process branching and
elongation by rat OPCs when co-applied with neurotro-
phic factors.30 Fingolimod can either promote or inhibit
rodent and human OPC differentiation in a dose-depen-
dent manner.27,30 Whereas the cytoskeletal dynamics of
rat mature OLGs in dispersed cell culture are not influ-
enced by fingolimod, this agent induces a cyclical regu-
lation of S1P1-dependent membrane elaboration and
S1P3/5-dependent membrane retraction in human ma-
ture OLGs over time.28 Astrocytes and microglia also
respond to S1P-directed signaling. S1P receptor en-
gagement in astrocytes leads to extracellular signal-reg-
ulated kinase-1/2 activation, resulting in proliferation and
neurotrophic factor production.31–33 Astrocytes addition-
ally produce platelet-derived growth factor (PDGF),
which can alter S1P receptor levels.34 Fingolimod can
inhibit macrophage infiltration following traumatic brain
injury.35
Although the effects of S1P receptor signaling on indi-
vidual neural cell types has been described, the direct
influence of fingolimod on neuroglial cells and myelin-
related processes in a physiological environment con-
taining all of the resident CNS elements, and the contri-
bution of individual S1P receptors to these responses,
have yet to be investigated. Here, we delineate the con-
sequence of fingolimod treatment on myelin maintenance
and remyelination, using an in vitro model that recapitu-
lates myelin-axon and cell-cell interactions. Rodents
orally administered 0.3 mg/kg of fingolimod daily over the
long-term were shown to have micromolar concentrations
of the active form of the drug within the brain paren-
chyma, whereas subnanomolar concentrations were
measured in the cerebrospinal fluid.22 Newborn mouse
organotypic cerebellar slice cultures were treated with
the active phosphorylated form of fingolimod at physio-
logical doses representative of those measured in the
brain (1 mol/L) and cerebrospinal fluid (100 pmol/L). We
have previously demonstrated that human neural cell
properties are modulated in vitro by fingolimod doses
within the range of 100 pmol/L to 1 mol/L.27,28 We had
observed that cells responded similarly when treated with
100 pmol/L to 1 nmol/L of fingolimod, or with 10 nmol/L to
1 mol/L of the drug.28 We report that fingolimod influ-
ences cells of the oligodendroglial lineage, microglia,
and astrocytes, resulting in enhanced remyelination in
the absence of a systemic immune system.
Materials and Methods
Animals and Tissue Preparation
Newborn (P0) wild-type CD1 mouse pups were obtained
from Charles River (Quebec, Canada). All procedures
were performed in accordance with the Canadian Coun-
cil on Animal Care guidelines. Slices were obtained and
cultured as previously described.36 Cerebellum and at-
tached hindbrain were extracted in L15 media and cut
into 300 m sagittal sections using a McIlwain tissue
chopper. Slices were separated and plated on a Milli-
pore-Millicel-CM culture insert (Fisher Scientific, Ottawa,
ON, Canada) in 6-well cell culture plates, with 6 slices per
insert. Culture media was composed of 50% minimal
essential media, 25% heat-inactivated horse serum, 25%
Earle’s balanced salt solution, 6.5 mg/ml glucose (Sigma-
Aldrich, St-Louis, MO), and penicillin and glutamine sup-
plements (All from Invitrogen, Carlsbad, CA). Membranes
were transferred into fresh media every 2 to 3 days.
Slices were left untreated for 21 days in vitro (DIV) to allow
clearance of debris and myelination to occur.37
Pharmacological Treatment
The active phosphorylated form of fingolimod was pro-
vided by Novartis Pharma (Basel, Switzerland) and was
reconstituted in dimethylsulfoxide/50 mmol/L HCl. Fin-
golimod was diluted in basal culture media and replaced
every 2 to 3 days. For myelin maintenance studies, cul-
tures were treated for three subsequent weeks with fin-
golimod. For remyelination studies, cultures were demy-
elinated with lysolecithin overnight (0.5 mg/ml), washed
with PBS twice for 10 minutes, allowed to recover in basal
culture media for 2 days, then treated with fingolimod for
the next 2 weeks (14 DIV). To investigate the response to
fingolimod independent from demyelination, control cul-
tures were allowed to recover for 14 DIV postlysolecithin,
then either left untreated for another 14 DIV (control 28
DIV postlysolecithin), or treated with fingolimod for 14 DIV
(total 28 DIV postlysolecithin). Cultures treated with the
vehicle used to reconstitute fingolimod showed no signif-
icant effects on myelin. To determine the mechanism of
fingolimod-induced effects, demyelinated cultures were
co-treated with fingolimod (100 pmol/L) and a S1P1 an-
tagonist W123 (1 mol/L; Cayman Chemicals, Ann Arbor,
MI) or a S1P3/5 pathway antagonist suramin (100 nmol/L;
EMD Bioscience, San Diego, CA).27–28 More specific S1P
receptor agonists were used to determine whether acti-
vation via specific S1P receptors could mimic the fingoli-
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mod-induced effects, including a S1P1 agonist SEW2871
(100 nmol/L; EMD Bioscience)27–28 and a S1P5 agonist
(100 nmol/L; provided by Novartis Pharma). The experi-
ments were performed on six different preparations.
Whole Mount Immunohistochemistry
Following two quick washes in PBS, slices were fixed in
1% paraformaldehyde (PFA) for 15 minutes for node of
Ranvier staining (Caspr and sodium channel), or 4% PFA
for 1 hour for all other stains, then washed twice in PBS.
Slices were cut from the membrane and blocked for 3
hours at room temperature in 1 mmol/L HEPES, 2% heat-
inactivated horse serum, 10% heat-inactivated goat se-
rum, 1% bovine serum albumin, and 0.25% Triton X-100
in Hank’s Balanced Salt Solution. Primary antibodies di-
luted in block solution were applied for 48 hours at 4°C.
These include mouse anti-myelin basic protein (MBP,
1:500; Sternberger Monoclonals Inc., Lutherville, MD),
rabbit anti-platelet-derived growth factor receptor 
(PDGFR, 1:50; Santa-Cruz Biotechnology, Santa Cruz,
CA), mouse anti-neurite outgrowth inhibitor protein A
(NogoA, 1:1000; provided by Dr.Martin Schwab, Univer-
sity of Zurich), polyclonal chicken anti-neurofilament me-
dium chain (NFM, 1:2000; EnCor Biotech, Alachua, FL),
mouse anti- tubulin III (-TubIII, 1:400; Sigma), rabbit
anti-ionized calcium binding adaptor molecule 1 (IBA-1,
1:500; Wako Chemicals USA, Richmond, VA), rabbit anti-
glial fibrillary acid protein (GFAP, 1:200; NeoMarkers,
Fremont, CA), mouse monoclonal pan anti-sodium chan-
nel (1:1000; Sigma), and rabbit anti-contactin associated
protein (Caspr, 1:10 000; provided by Dr. David Colman,
McGill University). Slices were washed thrice in PBS with
0.05% Triton X-100 for 1 hour on a rotary shaker then
incubated in secondary antibody diluted in block over-
night at 4°C. Secondary antibodies include goat anti-
mouse Cy3 (1:500; Jackson Immunoresearch, West
Grove, PA), donkey anti-chicken-Alexa-488 (1:70; Molec-
ular Probes, Eugene, OR), goat anti-mouse Alexa-488
(1:500; Molecular Probes), and goat anti-rabbit Cy3 (1:
250; Jackson ImmunoResearch). Slices were counter-
stained with nuclear dye Topro-3 (1:1000; Molecular
Probes), washed thrice, and mounted on glass slides
(Fisher Scientific) using Fluoromount G (Southern Bio-
tech, Birmingham, AL).
Immunohistochemical Analysis
Single optical 63 or 100 objective images were ac-
quired using a Zeiss LSM 510 microscope (Peabody,
MA). Two to three representative images were acquired
per stain per slice. The range of the slice was determined
using Z-stack imaging at 1- to 3-m intervals. By Z-stack
analysis, we found that slices thinned to approximately 30
m in culture. Analysis demonstrated that a fully myelin-
ated unmanipulated slice had three distinct regions in the
Z plane that differed in their cellular composition and
appearance: the first 1 to 5 m (‘top’) is where the
majority of the myelin, axons, OLGs, OPCs, and astro-
cytes reside; the next 6 to 23 m (‘middle’) have the
same composition as the ‘top’ layer however at lesser
amounts; the last 24 to 30 m (‘bottom’) was mostly
devoid of all cellular components except microglia, which
were also found throughout other depths of the slice
albeit at lower levels. Quantification was performed sep-
arately in the top and middle of the slice where the myelin
was located, to control for sampling error and variation in
thickness of each slice.
The area of MBP or GFAP immunostaining (m2) per
63 objective image was determined using Scion Image
software (Scion Corporation, Frederick, MD). The num-
bers of PDGFR, NogoA, and IBA-1 immunopositive cells
were counted in a blinded fashion either from represen-
tative63 objective images or a series of images derived
from Z-stack imaging. The number of nodes of Ranvier
per 100 objective image was determined by counting
areas of condensed sodium channel immunostaining
flanked by Caspr immunostaining. The diameter of the
Node of Ranvier (m) was evaluated by calibrating100
objective images and measuring the length of con-
densed sodium channel immunostaining using ImageJ
software (U. S. National Institutes of Health, Bethesda,
Maryland, http://rsb.info.nih.gov/ij).
Phagocytosis Assay
Phagocytosis of E. Coli-coated beads was used to mea-
sure phagocytic potential of microglia in the slices. A 2 l
drop of rhodamine-conjugated E. Coli bioparticles (1 mg/
ml; Invitrogen) reconstituted in culture media was added
directly on top of the slice. Slices were incubated for 3
hours at 37°C, then washed in PBS twice for 10 minutes,
and fixed in 4% PFA for 1 hour. Slices were then stained
against a microglial marker, IBA-1. Slices were kept in the
dark as much as possible during the fixation and immu-
nohistochemical staining processes. Absolute numbers
of phagocytic microglia were taken to be IBA-1 immu-
nopositive cells with red signal within the cell body, and
were counted in a blinded manner in images obtained
from Z-stacks. Phagocytosis assays were performed us-
ing one slice culture preparation.
Bromodeoxyuridine Incorporation
Bromodeoxyuridine (BrdU) incorporation and immuno-
histochemistry was performed as previously described.38
Briefly, BrdU was diluted in culture media to a concen-
tration of 10 mol/L and added to slices for 24 hours
before fixation in 4% PFA for 1 hour. Slices were dena-
tured with 2N HCl for 45 minutes, rinsed in PBS for 1
minute, then incubated with mouse anti-BrdU for 48 hours
(1:40; Sigma) and goat anti-mouse secondary antibody
overnight at 4°C.
Statistical Analysis
Values are represented as means  SEM, and some are
normalized to control cultures at the respective time
point. Statistical analyses were performed using one-way
analysis of variance (Newman-Keuls and Dunns multiple
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comparison tests), unpaired two-tailed Student’s t-test,
and Mann-Whitney test. P values less than 0.05 were
taken to represent significant differences between treat-
ment groups.
Electron Microscopy
Electron microscopy was used to confirm the integrity of
myelin and to assess actual remyelination as docu-
mented by thin myelin sheaths. Cerebellar slices were
fixed overnight with 2.5% glutaraldehye in 0.1 mol/L so-
dium cacodylate buffer then cut out of the surrounding
membrane, subsequently osmicated with potassium fer-
rocyanide-reduced 1% osmium tetroxide solution for 1
hour, and dehydrated with successive 10-minute washes
in increasing concentrations of ethanol. Slices were infil-
trated for 1 hour with 1:1, 1:2, and 1:3 ethanol: Epon
blends, followed by infiltration with pure Epon. Slices
were embedded in Epon in a plastic BEEM capsule.
Sections of 70 to 100 m were cut onto 200 mesh copper
grids and stained with 4% uranyl acetate and Reynold’s
lead citrate. Semithin sections of 1 m were stained with
toluidine-blue for neuropathological analysis.
Results
Characterization of Organotypic Cerebellar Slice
Cultures
To assess the role of fingolimod on remyelination, we
elected to use organotypic cerebellar slice cultures due
to previous studies demonstrating robust and reproduc-
ible myelination along definable axons in slices derived
from this brain region, and enhanced plasticity and resis-
tance to mechanical trauma at this age.36,37,39 Organo-
typic slices retain the astrocyte and microglia elements
that allow us to identify their contribution to myelination-
associated processes, but avoid the complex systemic im-
mune system interactions observed in intact animals. Con-
focal analysis of untreated slice cultures at the temporal
onset of pharmacological manipulation (21 DIV) indicated
that cultures were comprised of myelin (MBP), mature
oligodendrocytes (NogoA), neurons (NFM, TubIII),
OPCs (PDGFR), astrocytes (GFAP), and microglia
(IBA-1) (see Supplemental Figure 1A at http://ajp.
amjpathol.org). There was a significant co-localization be-
tween myelin (MBP) and axons (NFM) in the X, Y, and Z
axes (see Supplemental Figure S1, A and B, at http://
ajp.amjpathol.org). Cross-sectional analysis confirmed
that MBP fibers ensheathed NFM axons (see Supple-
mental Figure S1B at http://ajp.amjpathol.org). Not all
NFM immunopositive fibers were associated with MBP
staining, consistent with not all axons being myelinated in
organotypic cerebellar slices.37 Ultrastructural analysis
demonstrated that the myelin was compact and orga-
nized appropriately into nodes of Ranvier (see Supple-
mental Figure S1C at http://ajp.amjpathol.org), and was
therefore mature and of good integrity.
Effects of Fingolimod on Myelin Maintenance
and Oligodendroglia
Following recovery from dissection, cultures were treated
with the active phosphorylated form of fingolimod for the
subsequent 21 DIV then analyzed immunohistochemi-
cally. Fingolimod treatment (100 pmol/L, 1 mol/L) did
not significantly affect the area of MBP staining per
field relative to untreated cultures (0.97  0.3, 0.95 
0.2 fold over control, respectively), consistent with no
deleterious effects of fingolimod on myelin mainte-
nance (Figure 1A). We next investigated the effect of
fingolimod on mature OLGs, labeled with the OLG cell
body marker NogoA,40–41 and on OPCs identified by
PDGFR expression. Fingolimod treatment (100 pmol/L,
1 mol/L) induced membrane elaboration and process
outgrowth by OLGs (Figure 1B) and OPCs (Figure 1C),
respectively, relative to control. Fingolimod (100 pmol/L,
1 mol/L) had no significant impact on the absolute num-
ber of PDGFR cells, although a trend toward an
increase was observed with the lowest dose (12  2
and 6  1 per field, respectively, relative to 8  0 for
control) (Figure 1D). Fingolimod treatment for 21 DIV
(100 pmol/L) caused a significant decrease in numbers
of microglia (IBA-1) from 7  1 to 1  0 per field, and
a significant decrease in the area of GFAP immuno-
staining (from 3886  579 m2 to 2192  492).
Effects of Fingolimod on Remyelination and
Oligodendroglial Lineage Cells Following
Demyelination: Characterization of
Lysolecithin-Induced Demyelination
The bioactive lipid lysolecithin (lysophosphatidylcholine)
induces demyelination when focally injected into white
matter tracts such as the cerebellar peduncle and spinal
cord,42–43 or applied to organotypic slice cultures.37 Fol-
lowing 21 DIV of postisolation recovery, slices were
treated with 0.5 mg/ml lysolecithin for 16 hours, which
induces demyelination of organotypic slices by 2 days
postapplication while minimizing concomitant axonal in-
jury.37 Analysis of cultures 2 days after application of
lysolecithin indicated a notable decrease in the area of
MBP staining (0.23  0.18-fold over normally myelinated
control at 21 DIV) such that immunopositive staining was
associated with myelin debris and ensheathed axons
were rarely observed (Figure 2, A and B). In comparison
with toluidine-blue stained semithin sections from fully
myelinated controls (Figure 2C), sections from lysoleci-
thin-treated cultures demonstrated many demyelinated
fibers, few residually myelinated fibers, and accumulation
of myelin debris (Figure 2D). NFM staining was not ad-
versely affected by lysolecithin treatment indicating a
sparing of axons (Figure 2A). Fully myelinated cultures at
21 DIV demonstrated appropriately formed nodes of Ran-
vier characterized by paranodal Caspr immunostaining
flanking sodium channels localized to the node itself
(Figure 2E). Demyelination with lysolecithin caused a
lengthening of the distribution of sodium channels mark-
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ing the node (from 0.31  0.06 to 11.24  1.98 m2;
Figure 2F), a decrease in the average number of nodes of
Ranvier (from 22 3 to 7 2 nodes per field; Figure 2G),
and a dispersion of Caspr immunostaining; the latter has
been described in demyelinated MS lesions.44
Effects of Fingolimod on Recovery of Myelin
Following Lysolecithin-Induced Demyelination
Analysis of control cultures at 14 DIV postlysolecithin
(total 35 DIV) indicated that some recovery of MBP stain-
ing and ensheathment had occurred (1.4  0.42 com-
pared with 2 days postlysolecithin; Figure 3A); however,
remyelination was incomplete at this time point, as has
been previously documented in this culture system.37
Application of fingolimod (100 pmol/L, 1 mol/L) for 14
DIV following lysolecithin-induced demyelination caused
a significant increase in the area of MBP staining per field
relative to remyelinating control, indicative of enhanced
remyelination (1.97  0.33 and 2.00  0.40-fold over
control at 35 DIV, respectively) (Figure 3, A and B).
Ultrastructural evaluation of fingolimod-treated cultures
revealed many thin myelin sheaths, some of which were
associated with paranodes suggestive of functional re-
myelination (Figure 3C). These cultures maintained ap-
propriate cell–cell contacts and cyto-architecture as
demonstrated by synaptic associations and adjacent lo-
calization of astrocytes (Figure 3D). Whereas control
semithin toluidine-blue stained sections were character-
ized by many unmyelinated yet apparently healthy fibers
(Figure 3E), sections from fingolimod-treated cultures re-
vealed the presence of many thin myelin sheaths, some
thicker myelin sheaths, and healthy neurons and oligo-
dendrocytes (Figure 3F). As apparent in toluidine blue
stained sections, both control and fingolimod-treated
slices were characterized by the presence of phagocy-
tosed myelin debris; we could not appreciate any quali-
tative difference in the amount of MBP-immunoreactive
debris found in fingolimod-treated cultures compared
with control cultures at 14 DIV postdemyelination.
A time course analysis of remyelination was deter-
mined with various fingolimod treatment durations by
MBP immunohistochemistry. Remyelination was initiated
as early as 5 DIV postdemyelination in both control and
fingolimod-treated cultures. Although the area of MBP
immunostaining was not significantly different between
fingolimod treatment and control at both 5 and 12 DIV
(data not shown), it was only significantly enhanced with
fingolimod treatment at 14 DIV postlysolecithin (Figure 3,
A and B). This finding indicates that the fingolimod-in-
duced increase in remyelination occurred between 12
and 14 DIV following demyelination.
Effects of Fingolimod on Oligodendroglia During
Remyelination
Fully myelinated cultures at 21 DIV were characterized by
many NogoA mature OLGs (Figure 4A). Lysolecithin-in-
duced demyelination was associated with a loss of NogoA
immunostaining. Cells positive for another mature OLG-
associated cytoplasmic protein, adenomatous polyposis
coli/CC1, could still be observed under demyelinating con-
ditions (data not shown) suggesting that demyelination
eliminated myelin-associated NogoA but did not kill all
OLGs (Figure 4A). Control remyelinating cultures and fin-
golimod-treated cultures demonstrated a recovery of No-
Figure 1. Effect of fingolimod on myelin and oligodendroglial lineage cells
under nonpathological conditions. A: Quantification of amount of myelin
expressed as area of MBP immunostaining (m2) per 63 objective image
normalized to untreated control culture values at 35 days in vitro (DIV).
Treatment with fingolimod (100 pmol/L, 1 mol/L) for 21 DIV did not
significantly affect the amount of myelin in the cultures. B: Representative
confocal images of organotypic cerebellar slice cultures at 35 DIV immuno-
stained against the oligodendrocyte marker, neurite outgrowth inhibitor
protein A (NogoA; red). Untreated cultures were characterized by NogoA
positive mature oligodendrocytes that demonstrated some membrane fusion.
Treatment with fingolimod (100 pmol/L) for 21 DIV induced process out-
growth and membrane elaboration of NogoA positive cells relative to control.
Scale bar  20 m. C: Representative confocal images of organotypic cere-
bellar slices at 35 DIV immunostained against the oligodendrocyte progenitor
cell (OPC) marker platelet-derived growth factor receptor  (PDGFR; red)
and counterstained with the nuclear Topro-3 (blue). Some immunopositive
cells were observed in untreated cultures. Treatment with fingolimod (100
pmol/L) for 21 DIV caused process outgrowth in OPCs. Scale bar  20 m.
D: Quantification of absolute numbers of PDGFR OPCs per63 objective
image represented as average  SEM, at 35 DIV. There was a trend increase
in OPC numbers with 100 pmol/L fingolimod treatment for 21 DIV.
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goA immunostaining over 14 DIV of postlysolecithin recov-
ery (Figure 4A). At 14 DIV postlysolecithin, fingolimod
treatment (100 pmol/L, 1 mol/L) also induced a robust
outgrowth and elaboration of NogoA membranes com-
pared with remyelinating control (Figure 4A).
Lysolecithin treatment caused a significant increase in
absolute numbers of PDGFR OPCs (17  2 cells/
field), as compared with before lysolecithin treatment
(control at 21 DIV; 3  0 cells/field) (Figure 4, B and C).
The absolute number of OPCs was significantly de-
creased in control cultures at 14 DIV postlysolecithin (5
0 cells/field; Figure 4C), suggestive of initial differentia-
tion and loss of PDGFR expression. The low dose of
fingolimod (100 pmol/L) applied during 14 DIV postlyso-
lecithin induced process extension in OPCs (Figure 4B)
and caused a trend toward a relative increase in OPC
numbers (9  1 cells/field; Figure 4C).
Effects of Fingolimod on Microglia and
Astrocytes During Remyelination
To further evaluate the effects of fingolimod on neuroglial
cells in the context of enhanced remyelination, effects on
microglia and astrocytes were investigated. A time
course analysis demonstrated that average numbers of
IBA-1 microglia peaked at 2 DIV postlysolecithin, from
1  0 to 4  1 IBA-1 cells/field (Figure 5, A and B).
These numbers decreased by 5 DIV postlysolecithin and
were maintained at this level by 9 DIV and 14 DIV postly-
solecithin (Figure 5B), and may reflect the migration of
microglia out of the slice. Accordingly, there was a slight
increase in the number of IBA-1 cells at the edge of the
slice in these cultures (average 14 per field) compared
with 2 DIV postlysolecithin (average 10 per field).
Fingolimod-treated cultures (100 pmol/L) had a signif-
icant increase in microglia at 5 DIV postlysolecithin (5 
1 IBA-1 cells/field compared with 2  1 for control)
(Figure 5B). This was further increased by 9 DIV postly-
solecithin (14  2 compared with 2  1 for control), and
maintained by 14 DIV postlysolecithin (8  0 relative to
3 0 for control; Figure 5A, B). To determine whether this
microglial response in the presence of fingolimod could
be attributed to an enhanced response to demyelination,
cultures were left untreated for 14 DIV postlysolecithin
then subjected to another 14 DIV of fingolimod treatment
(100 pmol/L; total 28 DIV postlysolecithin). These cultures
still demonstrated a significant increase in microglia cell
numbers (13  1 IBA-1 cells/field) similar to that ob-
served when fingolimod was applied for 14 DIV immedi-
ately postlysolecithin (10  1) (Figure 5B). Significantly
more microglia were noted in this condition than in control
cultures at 28 DIV postlysolecithin (6  1; Figure 5B),
thereby dissociating this fingolimod-induced effect from
a response to demyelination.
When assessing astrocytic reactivity, the area of GFAP
immunostaining also peaked at 2 DIV postlysolecithin
Figure 2. Characteristics of lysolecithin-induced demyelination of slices. A: Representative images of slices at 21 DIV (pre-demyelination) and 2 DIV
postlysolecithin induced demyelination (23 DIV total), immunostained against myelin (MBP; red) and axons (NFM; green). Following lysolecithin treatment, MBP
immunostaining is not associated with axons and likely reflects myelin debris. Scale bar  20 m. B: Quantification of amount of myelin expressed as area of
MBP immunostaining (m2) per 63 objective image normalized to untreated control culture values at 21 DIV. Treatment with lysolecithin decreased the area
of MBP staining. *P  0.05. C: Representative toluidine-blue stained section of culture at 21DIV before demyelination. Arrows indicate myelinated fibers. Scale
bar 5 m. D: Representative toluidine-blue stained section of lysolecithin-treated culture 2 DIV postdemyelination demonstrates some residually myelinated
fibers (short arrow), many demyelinated axons (arrowheads), and some neurons showing some degenerative changes (long arrow). Myelin debris in the form
of small blue stained collections and granules is seen both within and outside of cells (MD). Scale bar  5 m. E: Immunostaining of cultures pre-lysolecithin
at 21 DIV demonstrates paranodal protein Caspr (red) flanking nodal aggregations of sodium channels (green), suggestive of proper node of Ranvier formation
(arrows). Lysolecithin-induced demyelination induced a dispersion of Caspr immunostaining (red) and expansion of sodium channels along the axon (green;
arrows). Scale bar  10 m. F: Average diameter of nodes of Ranvier (m) as measured by length of sodium channel aggregation  SEM, in cultures at 21 DIV
(pre-lysolecithin) or 2 DIV postlysolecithin-induced demyelination. Demyelination induced a significant increase in the length of the node due to lateral migration
of sodium channels. ***P  0.001. G: Average number of nodes of Ranvier per 63 objective image  SEM, in cultures at 21 DIV (pre-lysolecithin) or 2 DIV
postlysolecithin-induced demyelination. Demyelination induced a significant decrease in the number of nodes of Ranvier. *P  0.05.
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(2759  591 m2) compared with before demyelination
(624  220 m2) and subsided over the subsequent 14
DIV (1354  550 m2; Figure 5, C and D). Similar to the
effect on microglia cell numbers, fingolimod treatment
(100 pmol/L) for 14 DIV postlysolecithin was associated
with an increased area of GFAP immunostaining (4870 
83 m2; Figure 5, C and D). Consistent with the finding
that both astrocytes and microglia were increased in
cultures treated with fingolimod for 14 DIV postlysoleci-
thin, we observed a significant increase in cells that had
incorporated BrdU relative to remyelinating control (from
0.3  0.2 to 5  1 BrdU cells/field). The increased
numbers of microglia and increased immunoreactivity for
an astrocytic marker observed with fingolimod at 14 DIV
postlysolecithin coincided with the time when a signifi-
cant enhancement of remyelination was observed.
Previous studies have highlighted the importance of
phagocytosis of myelin debris in allowing remyelination to
proceed efficiently.17,39 Given the increased numbers of
microglia observed in demyelinated slices treated with
fingolimod for 14 DIV postlysolecithin, we determined
whether fingolimod may have enhanced the phagocytic
potential of microglia. Rhodamine-conjugated E. Coli-
coated beads were applied to the cultures for 3 hours
and numbers of IBA-1 and E. Coli-double positive cells
were quantified (see Supplemental Figure S2A at http://
ajp.amjpathol.org). A low basal level of phagocytosis was
observed in fully myelinated cultures at 21 DIV; numbers
of phagocytic cells were significantly increased by 5 DIV
postlysolecithin, which subsided significantly by 14 DIV
postlysolecithin. Fingolimod treatment (100 pmol/L) sig-
nificantly decreased the numbers of phagocytosing mi-
croglia at both 5 DIV (from 13  0 to 5  2) and 14 DIV
postdemyelination (from 4 1 to 1 1) (see Supplemen-
tal Figure S2B at http://ajp.amjpathol.org).
Functional Basis for the Effects of Fingolimod
During Remyelination
To investigate the mechanism through which fingolimod
enhanced remyelination in demyelinated slice cultures,
we compared the effects of co-treating cultures with fin-
golimod and antagonists of specific S1P receptor sub-
types on remyelination efficiency. Co-treatment of cul-
tures with fingolimod (100 pmol/L) and a S1P1 receptor
antagonist W123 only slightly decreased remyelination as
assessed by MBP immunohistochemistry (from 12.9 
Figure 3. Effects of fingolimod on remyelina-
tion following lysolecithin-induced demyelina-
tion. A: Representative images of demyelinated
slices, control or treated with fingolimod (100
pmol/L) for 14 DIV postlysolecithin, immuno-
stained against myelin (MBP; red) and axons
(NFM; green). Fingolimod increases the amount
of myelin associated with axons compared with
control. Scale bar  20 mol/L. B: Quantifica-
tion of amount of myelin expressed as area of
MBP immunostaining (m2) per 63 objective
image normalized to control culture values at 14
DIV postlysolecithin. Fingolimod treatment (100
pmol/L, 1 mol/L) for 14 DIV postlysolecithin
significantly increases the amount of myelin
compared with control cultures. *P  0.05. C:
Electron micrograph of demyelinated slice
treated with 100 pmol/L fingolimod for 14 DIV
postdemyelination indicates thin myelin sheaths
(arrows) suggestive of remyelination. Thin my-
elin sheaths at the paranode (PR) adjacent to the
node of Ranvier (NR) are suggestive functional
remyelination. Scale bar 1 m. D: Electron
micrograph of demyelinated slice treated with
100 pmol/L fingolimod for 14 DIV postdemyeli-
nation indicates maintenance of appropriate cy-
toarchitecture, with synaptic terminals (ST) onto
an axon (Ax) complete with synaptic vesicles,
with an adjacent astrocyte (As) likely mediating
homeostatic functions at the synapse. Scale
bar  0.5 m. E: Toluidine-blue stained image
of demyelinated slice allowed to recover for
14DIV postdemyelination. Arrowheads indi-
cate demyelinated axons. Arrows indicate thin
myelin sheaths suggestive of remyelination.
Scale bar  5 m. MD, myelin debris F: Tolui-
dine-blue stained image of demyelinated slice
treated with 100 pmol/L fingolimod for 14 DIV
postdemyelination demonstrates a healthy neu-
ron (N) and oligodendrocyte (O), as well as
many thin myelin sheaths (arrows) indicating
remyelination. Scale bar  5 m.
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4.1 to 7.2  1.3 fold over control; Figure 6, A and B).
However, fingolimod co-treatment with a S1P3/S1P5
pathway antagonist suramin (100 nmol/L) significantly
reversed the enhanced remyelination observed with fin-
golimod alone (to 2.5  1.0 fold over control; Figure 6,
A–C). These results suggest that fingolimod enhanced
remyelination in the cultures primarily through S1P3/S1P5
signaling. Accordingly, remyelination was inhibited and
MBP immunoreactivity was associated with myelin debris
when a S1P1 agonist SEW2871 (100 nmol/L) was applied
alone to the cultures, whereas a trend increase in remy-
elination was observed with a S1P5 specific agonist (100
nmol/L; 2.6  1.6 fold over control).
We next assessed how these effects of specific S1P
receptor blocking and activation correlated to astrocyte
and microglial responses in the slice. The increased as-
trocytic response observed at 14 DIV postlysolecithin
with fingolimod treatment was significantly increased
when W123 was supplemented to cultures (from 3. 0 
0.3 to 7.1  0.2 fold over control), whereas suramin
supplementation significantly reversed values compared
with fingolimod alone (1.3  0.5 fold over control; Figure
7, A and B). These findings suggest that whereas S1P3/5
signaling promotes astrogliosis, this is inhibited by S1P1
signaling, and blocking the latter further increases the
astrocytic response induced by fingolimod. In support of
this, SEW2871 applied to demyelinated cultures signifi-
cantly decreased the area of GFAP immunostaining com-
pared with control (0.5  0.1 fold), whereas a S1P5
agonist induced a trend increase in values (1.3 0.5 fold
over control; Figure 7B).
The increase in microglia cell numbers observed at 14
DIV postdemyelination with fingolimod treatment alone
(6.4  0.8 fold over control) were slightly yet not signifi-
cantly decreased with W123 co-treatment (5.1 0.5), yet
were increased when suramin was supplemented to the
cultures (10.7  1.0). We observed that treatment with
SEW2871 or the S1P5 agonist was able to induce a
significant increase in microglia cell numbers (6.2  0.2
and 5.4  0.4 fold over control, respectively). Together,
the data suggests that signaling through S1P1 and S1P5
can contribute to enhanced microgliosis, yet the increase
in cell numbers consequent to S1P3/5 blockade via
suramin implies that S1P3 signaling may suppress this
response. The increase in microglia cell numbers in the
SEW2871-treated condition, where remyelination was in-
hibited, demonstrates that S1P receptor-driven enhance-
ment of microgliosis is not sufficient to drive the myelin
repair response.
Discussion
Effect of Fingolimod on Myelin Maintenance
Long-term treatment (21 DIV) of fully myelinated organo-
typic cerebellar slice cultures with both low (100 pmol/L)
and high (1 mol/L) doses of fingolimod did not induce
any deleterious effect on myelin maintenance. Fingoli-
mod promoted the elaboration of membranous lamellipo-
dial extensions by OPCs and OLGs, and increased OPC
cell number. The elaboration of processes is critical for
myelination to proceed45 and precise regulation of pro-
cess extension is required for OPC migration and differ-
entiation into mature OLGs.46–47 Our previous studies in
vitro demonstrated that fingolimod induces process ex-
tension by human-derived OPCs and mature OLGs under
basal culture conditions.27–28 We demonstrate that fin-
golimod-induced oligodendroglial membrane elaboration
was not sufficient to increase the amount of MBP in the
cultures. We hypothesize that all fibers that could be
myelinated within the culture may have already been
ensheathed thereby preventing any increase in myelina-
tion. In contrast with the findings we present here using
organotypic slices, rodent OLGs in dispersed cell cul-
tures do not modulate their cytoskeleton in response to
the drug,28 and fingolimod alone has no effect on rodent
and human OPC cell numbers.27,34 These findings indi-
cate that OLGs and OPCs may either modulate their S1P
receptor levels in an environment containing multiple cell
types, or that they are responding to factors being re-
Figure 4. Effects of fingolimod on oligodendroglial lineage cells under
remyelinating conditions. A: Representative images of mature oligodendro-
cytes immunostained against NogoA (red). Cultures at 2 DIV postlysolecithin
demonstrate a loss of NogoA immunoreactivity; control cultures at 14 DIV
postlysolecithin show some recovery of NogoA immunostaining. Fingolimod
treatment for 14 DIV postlysolecithin induces extension of processes in
mature oligodendrocytes relative to control. Scale bar  20 m. B: Repre-
sentative images of OPCs immunostained against PDGFR (red) and coun-
terstained with the nuclear dye Topro-3 (blue) demonstrate an increase in
OPC numbers in cultures 2 DIV postlysolecithin, and a subsequent decrease
in control cultures at 14 DIV postlysolecithin likely representing differentia-
tion and loss of the marker. Process extension was observed in OPCs in
cultures treated with fingolimod for 14 DIV postlysolecithin. Scale bar  20
m. C: Quantification of absolute numbers of PDGFR immunopositive
OPCs per63 objective image SEM. At 2 DIV postlysolecithin, numbers of
OPCs are significantly increased compared with pre-lysolecithin (control 21
DIV). These numbers subsequently decrease by 14 DIV postlysolecithin in
control cultures. Fingolimod treatment (100 pmol/L) for 14 DIV postlysole-
cithin induced a trend toward an increase in OPC numbers. **P  0.01.
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leased by other fingolimod-stimulated neuroglial cells in
the slice.
Effects of Fingolimod on Remyelination
Demyelination was induced in cerebellar slice cultures by
overnight treatment with lysolecithin, inducing a loss of
MBP associated with axons, an increase in MBP immu-
nostaining resembling debris, a decrease in the fre-
quency of nodes of Ranvier, and a lengthening of the
nodal region.
The adult CNS undergoes at least partial repair follow-
ing injury. Myelin repair occurs via remyelination, and is
considered to be associated with recovery of axonal
function and clinical remittance.13,14,48 Studies of orga-
notypic cerebellar slice cultures indicate that following a
transient insult with lysolecithin, OPC differentiation and
re-expression of myelin proteins occurs in the same tem-
poral succession that would be observed in vivo.37 These
studies demonstrated that the remyelination process is
initiated within 1 week of demyelination, yet remains lim-
ited at 11 DIV postdemyelination.37 To document remy-
elination, we used MBP immunohistochemistry, which
has previously been used to monitor this process in slice
cultures, and co-labels with the late differentiation marker
myelin oligodendrocyte glycoprotein by 11 DIV postd-
emyelination.37 Consistent with previous studies, the cer-
ebellar slice cultures used in our current study initiated
remyelination within 5 days of demyelination and under-
went observable yet incomplete remyelination by 14 DIV
postdemyelination. At 14 DIV postdemyelination, treat-
ment with both high and low doses of fingolimod in-
creased the amount of MBP immunostaining in demyeli-
nated cultures in comparison with control. Toluidine-blue
stained sections and ultrastructural analysis revealed the
presence of many thin myelin sheaths in fingolimod-
treated cultures suggestive of remyelination. Our findings
using S1P receptor specific agonists and antagonists
suggest that fingolimod enhanced remyelination primarily
via S1P3/5 signaling; engagement of S1P5 was sufficient
to induce a trend increase in remyelination. S1P5 is highly
expressed on mature oligodendrocytes,28,29 and S1P5-
Figure 5. Effects of fingolimod on microglia and astrocytes under remyelinating conditions. A: Representative images of slices at 35 DIV immunostained against
the microglial marker IBA-1 (red). Microglia are increased at 2 DIV postlysolecithin and subsequently decrease by 14 DIV. Cultures treated with fingolimod (100
pmol/L) for 14 DIV postlysolecithin show relatively increased numbers of microglia relative to control cultures. Scale bar  20 m. B: Quantification of numbers
of microglia represented as average IBA-1 immunopositive cells per 63 objective image  SEM. Microglia cell numbers are increased by 2 DIV postlysolecithin,
which subsides by 5 DIV. Fingolimod-treated cultures (Fing; black bars) showed a significant increase in microglia cell numbers at 5, 9, and 14DIV
postdemyelination compared with controls (Ctrl; white bars). Delaying 14 DIV fingolimod treatment for 2 weeks following lysolecithin treatment still induced an
increase in microglia cell numbers in comparison with control cultures at 28 DIV postlysolecithin. *P  0.05, **P  0.01, ***P  0.001. C: Representative images
of slices at 35 DIV immunostained against the astrocytic marker GFAP (red). Astrocytes are increased at 2 DIV postlysolecithin and subsequently decrease by 14
DIV. Cultures treated with fingolimod (100 pmol/L) for 14 DIV postlysolecithin show relatively increased GFAP immunostaining relative to control cultures. Scale
bar 20 m. D: Quantification of astrocytes represented as area of GFAP immunostaining (m2) SEM. Demyelination with lysolecithin (2 DIV postlysolecithin)
induces an increase in GFAP staining compared with pre-demyelination controls (21 DIV). In 14 DIV postlysolecithin control cultures, GFAP staining shows a
relative decrease compared with 2 DIV postlysolecithin. Fingolimod treatment (100 pmol/L) for 14 DIV postlysolecithin induces an increase in GFAP staining, as
compared with control. **P  0.01, ***P  0.001.
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mediated signaling has pro-survival effects on human
and rodent mature oligodendrocytes.28,29 Whereas our
studies using dissociated cultures of human OPCs dem-
onstrated that S1P1 signaling could promote process
extension, differentiation, and survival,27 here we ob-
served that signaling through this receptor inhibited re-
myelination. One postulate for this unexpected result is
that the growth factor environment within the slice may
have modulated responses to fingolimod. Previous stud-
ies have demonstrated how responses to S1P receptor
modulators may be influenced by growth factors, for
instance PDGF and S1P receptor signaling are coordi-
nated and this growth factor regulates expression levels
of S1P receptors.34
The increase in absolute numbers of PDGFR positive
OPCs following lysolecithin treatment is consistent with
the previously documented incorporation of BrdU into
PDGFR cells in lipopolysaccharide-treated organo-
typic cultures49 and increased OPC proliferation follow-
ing demyelination in vivo.15 Whereas OPC numbers sub-
sequently subsided over time in control cultures, by 14
DIV postlysolecithin, fingolimod treatment induced a
trend increase in absolute numbers of OPCs. Increased
OPC numbers may have reflected enhanced survival or
proliferation, which have been documented to occur in
dissociated cultures.27,30,34 More OPCs may have been
available to participate in remyelination compared with
control conditions. We hypothesize that the number of
PDGFR cells may not have reached significance with
fingolimod treatment due to a putative acceleration of
OPC differentiation and consequent loss of PDGFR ex-
pression. Fingolimod also induced process extension by
both OPCs and OLGs under remyelinating conditions.
Low doses of fingolimod induce differentiation of rat
OPCs into mature OLGs in dissociated cultures whereas
high doses have the opposite effect.30,34 In our slices,
OPCs may not have been exposed to high enough doses
of the drug required to inhibit differentiation, perhaps as
a result of sequestration by OLGs/myelin.22
Effects of Fingolimod on Microglia and
Astrocytes Under Remyelinating Conditions
We observed that microglial cell numbers peaked at 2
DIV postlysolecithin and declined by 14 DIV postlysole-
Figure 6. Mechanism of fingolimod-mediated effects on remyelination. A:
Representative images of myelin (MBP) in cultures at 14 DIV postdemyeli-
nation, treated with fingolimod (100 pmol/L) alone, or co-treated with a S1P1
receptor antagonist W123 or a S1P3/5 pathway antagonist suramin. Scale
bar  20 m. B: Quantification of amount of myelin expressed as area of
MBP immunostaining (m2) per 63 objective image normalized to control
culture values at 14 DIV postlysolecithin. The increased remyelination ob-
served with fingolimod treatment (100 pmol/L) for 14 DIV postlysolecithin
was slightly decreased with W123 co-treatment, yet was only significantly
reversed with suramin supplementation. *P  0.05, **P  0.01. C: Represen-
tative images of cultures treated with specific S1P receptor agonists for 14
DIV following demyelination. The S1P1 agonist SEW2871 (100 nmol/L)
caused a decrease in the amount of myelin associated with axons and
increase of myelin debris. A S1P5 agonist (100 nmol/L) induced trend in-
creases in remyelination. Scale bar  20 m.
Figure 7. Mechanism of fingolimod-induced effects on astrocytes. A: Rep-
resentative images of GFAP immunostaining of cultures at 14 DIV postdemy-
elination. The increase in GFAP immunostaining observed with fingolimod
treatment (100 pmol/L) was further increased when the S1P1 antagonist
W123 was supplemented to the cultures, suggesting a disinhibition of S1P3/
5-associated signaling. Accordingly, suramin supplementation significantly
decreased the area of GFAP immunostaining compared with fingolimod
alone. Scale bar  20 m. B: Quantification of the astrocytic response
represented as area of GFAP immunostaining (m2) normalized to control at
14 DIV postdemyelination. Fingolimod-induced increase in values were
significantly increased by W123 and reversed with suramin. The S1P1 agonist
SEW2871 (100 nmol/L) significantly decreased GFAP immunostaining, as
compared with control, whereas a S1P5 agonist (100 nmol/L) had no signif-
icant effect. *P  0.05, **P  0.01.
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cithin in control cultures. Previous studies have demon-
strated the abundance of microglia in these cultures and
their activation consequent to demyelination.37 Microglia
are increased in numbers by 3 days following ethidium
bromide-induced demyelination in vivo with concomitant
increases in PDGFR OPCs at the lesion border.50
Fingolimod-treated cultures demonstrated an increase in
microglia cell numbers by 5 DIV following demyelination
that was maintained to at least 14 DIV postdemyelination.
When the drug application (for 14 DIV) was delayed by 2
weeks, the increase in microglia numbers was still de-
tected, suggesting that its occurrence was not a conse-
quence of a response to demyelination. One key mech-
anism whereby macrophages/microglia contribute to
remyelination involves their capacity to phagocytose my-
elin debris, as confirmed by depletion of these cells with
clodronate-liposomes.16,17 Using fluorescently-conju-
gated bacteria as an index of phagocytic activity, we
observed a peak in numbers of phagocytic microglia
shortly after demyelination (2 and 5 DIV) in control cul-
tures. In cultures exposed to fingolimod, a decrease in
the absolute numbers of actively phagocytic cells was
detected at 5 and 14 DIV postlysolecithin. Although fin-
golimod treatment may have reduced the number of
phagocytic microglia, the increase in total numbers of
microglia could have been sufficient to result in myelin
debris ingestion such that remyelination could occur.
Ultrastructural analysis of fingolimod-treated slices indi-
cated the presence of phagocytosed myelin debris; we
could not appreciate any qualitative difference in the
amount of MBP-immunoreactive debris found in fingoli-
mod-treated cultures compared with control cultures at
14 DIV postdemyelination. Our studies using S1P receptor
specific agonists and antagonists suggest that signaling via
S1P1 and S1P5 contribute to microgliosis, whereas S1P3-
mediated signaling may inhibit this response. The increase
in microglia cell numbers under treatment conditions that
either promoted remyelination (fingolimod, S1P5) or inhib-
ited remyelination (SEW2871) suggest that S1P receptor-
mediated enhancement of microglia numbers may have
contributed to, but was not sufficient for, myelin repair.
We observed an increase in GFAP immunoreactivity by
2 DIV following demyelination, which subsided by 14 DIV
in control cultures. We observed increased GFAP immu-
noreactivity at 14 DIV postlysolecithin when fingolimod
was applied to cultures. Although astrocytes are associ-
ated with formation of a glial scar, destruction of tissue,
and production of factors that can inhibit OPC prolifera-
tion and maturation (ie, tumor necrosis factor-),51 they
have the capability to produce factors that can enhance
OPC function. Astrocytes have been suggested to be
beneficial in an acute inflammatory environment soon
after demyelination.52 Astrocytes stimulated with pro-in-
flammatory cytokines in vitro or found at the edge of
active MS lesions produce growth factors and chemo-
kines that can influence OPC survival, differentiation, mi-
gration, and remyelination.18,19,53 Furthermore, S1P re-
ceptor activation in cultured astrocytes leads to nerve
growth factor production.54 Injection of exogenous astro-
cytes into spinal cord lesions enhances remyelination,55
and remyelination of such lesions is only seen in the
astrocytic perimeter.56 A lack of remyelination has been
observed in regions devoid of astrocytes.57 Application
of S1P receptor specific agonists and antagonists re-
vealed that the fingolimod-induced increase in astroglio-
sis was mediated primarily through S1P3/S1P5, whereas
S1P1 signaling appeared to inhibit this response. In com-
parison, one study using dissociated astrocyte cultures
has implicated S1P1 in astrocyte proliferation.33 How-
ever, other studies have demonstrated that S1P or fingoli-
mod-mediated signaling and functional effects in disso-
ciated cultures of rodent astrocytes are mediated via
Gi
56,58–60; Gi can be associated with S1P5 activation.
61
An alternative explanation for this discrepancy is that
fingolimod effects on neuroglia within the slice may have
caused the release of factors that modulated the astro-
cytic response. In support of this postulate, S1P receptor
engagement on astrocytes can induce growth factor pro-
duction54,62 and growth factors can modulate S1P recep-
tor gene expression in rat astrocytes in an autocrine
manner such that S1P5 levels are increased.63 This sug-
gests that within a physiological environment, astrocytes
may primarily respond to fingolimod via S1P5, rather than
through S1P1 as predicted from isolated cultures. Interest-
ingly, treatment conditions under which astrogliosis was
enhanced (fingolimod, S1P5) coincidedwith those sufficient
to ameliorate remyelination, further supporting the beneficial
role of astrocytes in the remyelination process.
Conclusion
Our studies suggest that fingolimod enhanced remyeli-
nation, which was well-correlated with an astrocytic re-
sponse, both mediated via S1P3/S1P5, whereas a S1P1-
and S1P5-dependent increase in microglia cell numbers
and effects on phagocytosis did not appear sufficient to
enhance the myelin repair process. These data establish
that S1P receptor-specific signaling on multiple neuro-
glial cell types in a physiological environment can influ-
ence remyelination, in a manner that may not have been
predicted from dissociated culture studies.
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